Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
-- Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved a two point reduction in NAS (NAFLD activity score) on biopsy --
-- Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved resolution of
-- A ≥30% fat reduction (MRI-PDFF) in MGL-3196 treated patients, at Week 12 predicted an improved
-- MGL-3196 was well-tolerated with mostly mild and a few moderate AEs; 7 SAEs, none drug related, none occurring more than once, 5 in MGL-3196, 2 in placebo-treated patients (study randomized 2:1) --
-- Conference call scheduled for
|MGL-3196||MGL-3196 MRI-PDFF Responders1||Placebo|
|Number of patients with baseline and end-of-study liver biopsies2||73||46||34|
|≥ 2 Point Decrease in NAS||
1MGL-3196 MRI-PDFF Responders = MGL-3196 treated patients with >=30% relative fat reduction on Week 12 MRI-PDFF
2does not include one end-of-study liver biopsy that was inadequate
- MGL-3196 treated patients with ≥ 30% fat reduction on MRI-PDFF at Week 12 demonstrated a higher percentage of NAS reduction and
- In patients with NASH Resolution, 35% of MGL-3196 treated and no placebo patients had baseline NAS ≥5
- In MGL-3196 patients with
NASHresolution, fibrosis also resolved in 50% of patients and was decreased statistically significantly relative to all placebo patients.
Other Week 36 endpoints and safety:
- Sustained, highly statistically significant (p<0.0001) reduction in liver fat compared with placebo on Week 36 MRI-PDFF; mean relative fat reduction MGL-3196 37%; placebo, 8.9%
- Sustained, statistically significant reductions in low-density lipoprotein cholesterol (LDL-C), triglycerides, ApoB and lipoprotein(a)
- Statistically significant reductions in liver enzymes, of greater magnitude with longer duration of MGL-3196 treatment. Statistically significantly more MGL-3196 treated than placebo patients had normalization of ALT
- Statistically significant reductions in fibrosis biomarkers in treated compared with placebo patients
- On liver biopsy, fibrosis was reduced by at least 1 point in 23% of placebo and 29% of MGL-3196 treated patients
- Very good all subject tolerability: mostly mild and a few moderate AEs which were balanced between drug treated and placebo patients
- An increase in incidence of a transient mild diarrhea at beginning of study, often a single episode, in MGL-3196-treated compared with placebo
“NASH is a common liver disease in
“The degree of
Conference Call and Webcast Information
Madrigal will hold a conference call and webcast this morning at
The conference call will also be webcast live and can be accessed at http://www.madrigalpharma.com/newsroom/presentations/ in the “Events and Presentations” section of the Madrigal website.
If you are unable to participate, a replay of the conference call will be available on the website under http://www.madrigalpharma.com/newsroom/presentations/.
Clinical Program Summaries for MGL-3196
Non-alcoholic Steatohepatitis (
In October 2016, the first patient was treated in the ongoing Phase 2 trial of MGL-3196 for the treatment of
Patients were randomized to receive either MGL-3196 or placebo in a 2:1 ratio.
The primary endpoint of the study, the reduction of liver fat at 12 weeks compared with baseline (relative change), assessed by MRI-PDFF, was achieved. Liver fat was reduced by 36.3% in all MGL-3196 treated patients (78) and 42.0% in a pre-specified group of high exposure MGL-3196 treated patients (44/78), as compared with 9.6% median reduction in liver fat in 38 placebo treated patients. These results were statistically significant (p<0.0001) for both MGL-3196 treatment groups. Further, 75% of the high-exposure MGL-3196 treated patients showed liver fat reductions of ≥30%. MGL-3196 treated patients also showed significant reductions relative to placebo in multiple atherogenic lipids including LDL-cholesterol, Lp(a), Apo B and triglycerides. At Week 12, there were statistically significant reductions in MGL-3196 compared with placebo patients in liver enzyme, inflammatory and fibrosis biomarkers, consistent with a potential of MGL-3196 to reduce
Between Weeks 12 and 36, 4 placebo patients discontinued, 1 of the 4 had a repeat liver biopsy (Week 26) and was considered a completer, and one 36 week completer did not have a Week 36 liver biopsy; 4 MGL-3196 patients discontinued, and one week 36 patient had a repeat liver biopsy that was inadequate. Six of eight discontinuations were either lost to follow up or patient decision; one in each treatment group was related to an AE. No SAEs were related to treatment or occurred more than once. Most SAEs were related to a pre-existing condition and resolved or improved with treatment. The two SAEs in the placebo group were choledocholithiasis and pain from an umbilical hernia; in the MGL-3196 group, the SAEs were an aborted CVA occurring a few days after randomization, a kidney stone, a C. difficile colitis, an intra-abdominal bleed post end-of-study liver biopsy, and a worsening of spinal stenosis. In the placebo group, one patient’s end-of-study liver biopsy had progressed from Stage 2 fibrosis at baseline to Stage 4, cirrhosis.
In addition, based on liver enzyme inclusion criteria, some patients are receiving extended treatment beyond 36 weeks for up to 36 additional weeks. All patients in this extension study will receive MGL-3196 and only non-invasive assessments will be made, including serial MRI-PDFF, safety labs, and circulating biomarkers. Additional information about the study [NCT02912260] can be obtained at www.ClinicalTrials.gov.
Heterozygous familial hypercholesterolemia (HeFH), and a much rarer form called homozygous familial hypercholesterolemia (HoFH), are severe genetic dyslipidemias typically caused by inactivating mutations in the LDL receptor. Both forms of FH lead to early onset cardiovascular disease. HeFH, the most common dominantly inherited disease, is present in up to 1 in 200 people and as many as 40 percent of HeFH patients are not able to reach their cholesterol (LDL-C) reduction goals on these therapies, reflecting the lifetime burden of cholesterol buildup in their bodies.
In a completed Phase 2 HeFH trial, patients who were not at their LDL-C goal were randomized in a 2:1 ratio to receive either MGL-3196 or placebo, in addition to their current cholesterol lowering regimen, which included approximately 75% taking high intensity statins (20/40 mg rosuvastatin or 80 mg atorvastatin), and about 2/3 of patients also taking ezetimibe. MGL-3196 treated patients (placebo corrected) achieved highly significant (p<0.0001) LDL-C lowering of 18.8%, and 21% LDL-C lowering in those on an optimal dose of MGL-3196. LDL-C lowering was 28.5% in MGL-3196 treated compared to placebo in a prespecified group of patients who did not tolerate high intensity statin doses. Highly significant reductions (p<0.0001) relative to placebo were also observed with ApoB, triglycerides (TG) (25-31%), apolipoprotein CIII (Apo CIII) and Lp(a) (25-40%) in all MGL-3196 treated patients and prespecified subgroups, irrespective of statin treatment.
MGL-3196 was well-tolerated with primarily mild and some moderate AEs, the numbers of which were balanced between placebo and drug-treatment groups.
Among its many functions in the human body, thyroid hormone, through activation of its beta receptor, plays a central role in controlling lipid metabolism, impacting a range of health parameters from levels of serum cholesterol and triglycerides to the pathological buildup of fat in the liver. Attempts to exploit this pathway for therapeutic purposes in cardio-metabolic and liver diseases have been hampered by the lack of selectivity of older compounds for the thyroid hormone receptor (THR)-β, chemically-related toxicities and undesirable distribution in the body.
Madrigal recognized that greater selectivity for thyroid hormone receptor (THR)-β and liver targeting might overcome these challenges and deliver the full therapeutic potential of THR-β agonism. Madrigal believes that MGL-3196 is the first orally administered, small-molecule, liver- directed, truly β-selective THR agonist. MGL- 3196 has demonstrated the potential for a broad array of therapeutically beneficial effects, improving components of both metabolic syndrome, such as insulin resistance and dyslipidemia, and fatty liver disease, including lipotoxicity and inflammation. These pleiotropic actions, coupled with an excellent safety profile, suggest that MGL-3196 could be the preferred treatment option for
This communication contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements contain words such as “expect,” “could,” “may,” “will,” “believe,” “estimate,” "continue," "future,” or the negative thereof or comparable terminology and the use of future dates. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's clinical development of MGL-3196, the timing and outcomes of clinical studies of MGL- 3196, and the uncertainties inherent in clinical testing. Undue reliance should not be placed on forward- looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal's filings with the
Source: Madrigal Pharmaceuticals, Inc.